08:45 AM EST - Bee Vectoring Technologies International Inc : Announces it is exploring strategic alternatives, including a potential sale, to enhance the Company’s ability to bring innovative biocontrol technologies to market. This decision is driven by the goal of identifying a more capitalized parent company that can amplify the commercial success of BVT’s groundbreaking solutions. BVT has demonstrated success with its proprietary biological control agent, Clonostachys rosea strain CR-7, in global field trials and is witnessing the early stages of commercialization. Bee Vectoring Technologies International Inc
shares C.BEE are trading unchanged at $0.01.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=BEE%3ACNX&qmodStoryID=6492152260953233
